Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors

Neuro-Oncology

Volumn 11, Issue 6, 2009, Pages 825-832

  Armstrong, Terri S ^a,b   Cao, Yumei ^b   Scheurer, Michael E ^c   Vera Bolaños, Elizabeth ^b   Manning, Rochelle ^b   Okcu, Mehmet F ^c   Bondy, Melissa ^b   Zhou, Renke ^b   Gilbert, Mark R ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Brain tumors; Chemotherapy; Myelotoxicity

Indexed keywords

ANALGESIC AGENT; CORTICOSTEROID; CREATININE; DNA METHYLTRANSFERASE; GLUTATHIONE TRANSFERASE P1; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BODY SURFACE; BONE MARROW TOXICITY; FEBRILE NEUTROPENIA; FEMALE; GASTROESOPHAGEAL REFLUX; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; GLIOMA; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASM STAGING; NEUTROPENIA; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOPENIA; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 73249126947     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-120     Document Type: Article

References (24)

1. Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11(2):165-180.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
3. Schering-Plough. Temozolomide prescribing information. Version 3/14/05. Schering-Plough Research Institute, Kenilworth, NJ. 2005. Available at http://www.spfiles.com/pitemodar.pdf. Accessed February 21, 2009.
4. Doyle TJ, Middelsen T, Croteau D. Fatal hematologic toxicity with prolonged continuous administration of temozolomide (TMZ) during radiation therapy (RT) in the treatment of newly-diagnosed glioblastoma multiforme (GBM): Report of a phase II trial [abstract]. J Clin Oncol. 23(16 suppl):1546.
5. Gerber DE, Grossman SA, Zeltzman M, Parisi MA, Kleinberg L. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro-Oncology. 2007;9(1):47-52.
6. Jalali R, Singh P, Menon H, Gujral S. Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with temozolomide. J Neurooncol. 2007;85(1):105-107.
7. Noronha V, Berliner N, Ballen KK, et al. Treatment-related myelodysplasia/ AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro-Oncology. 2006;8(3):280-283.
8. Singhal N, Selva-Nayagam S, Brown MP. Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment-case study and review of literature. J Neurooncol. 2007;85(2):229-230.
9. Armstrong TS, et al. Neutropenia with first course temozolomide: the "X" factor. Presented at: Annual Meeting of the ENO/SNO; 2005; Edinburgh, Scotland.
10. National Cancer Institute. NCI CTCAE Version 3. 2006. Available at http://ctep.cancer.gov/ProtocolDevelopment/electronic-applications/docs/ctcaev3. pdf. Accessed February 21, 2009. 9.
11. Smith TJ, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187-3205.
12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors, V.1.2007. Available at http://www.cnnc.org/ professionals/physicians-gls/pdf/myeloid-growth.pdf. Accessed October 31, 2007.
13. Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res. 2006;12(18):5481-5490.
14. Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol. 2008;83:1-10.
15. Fattinger K, Roos M, Vergères P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol. 2000;49(2):158-167.
16. Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. J Clin Pharmacol. 1998;38(11):1003-1009.
17. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 1992;22(1):1-21.
18. Burchell B, Brierley CH, Rance D. Specificity of human UDPglucuronosyltransferases and xenobiotic glucuronidation. Life Sci. 1995;57(20):1819-1831.
19. Jenkins P, Elyan S, Freeman S. Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. Eur J Cancer. 2007;43(3):544-548.
20. Hurria A, Lichtman SM. Pharmacokinetics of chemotherapy in the older patient. Cancer Control. 2007;14(1):32-43.
21. Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst. 1990;82(4):323-325.
22. Friedman HS. DNA mismatch repair and 06-alkylguanine-DNA methyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16(12):3851-3817.
23. Margison GP, Heighway J, Pearson S, et al. Quantitative trait locus analysis reveals two intragenic sites that influence O6-alkylguanine-DNA alkyltransferase activity in peripheral blood mononuclear cells. Carcinogenesis. 2005;26(8):1473-1480.
24. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P) H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact. 2000;129(1-2):77-97.